Chiral Aromatase and Dual Aromatase−Steroid Sulfatase Inhibitors from the Letrozole Template: Synthesis, Absolute Configuration, and In Vitro Activity
- 1 July 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (14) , 4226-4238
Abstract
To explore aromatase inhibition and to broaden the structural diversity of dual aromatase−sulfatase inhibitors (DASIs), we introduced the steroid sulfatase (STS) inhibitory pharmacophore to letrozole. Letrozole derivatives were prepared bearing bis-sulfamates or mono-sulfamates with or without adjacent substituents. The most potent of the achiral and racemic aromatase inhibitor was 40 (IC50 = 3.0 nM). Its phenolic precursor 39 was separated by chiral HPLC, and the absolute configuration of each enantiomer was determined using vibrational and electronic circular dichroism in tandem with calculations of the predicted spectra. Of the two enantiomers, (R)-phenol (39a) was the most potent aromatase inhibitor (IC50 = 0.6 nM, comparable to letrozole), whereas the (S)-sulfamate, (40b) inhibited STS most potently (IC50 = 553 nM). These results suggest that a new structural class of DASI for potential treatment of hormone-dependent breast cancer has been identified, and this is the first report of STS inhibition by an enantiopure nonsteroidal compound.Keywords
This publication has 56 references indexed in Scilit:
- Aromatase inhibitors in early breast cancer therapy: a variety of treatment strategiesExpert Opinion on Pharmacotherapy, 2006
- Refining the postmenopausal breast cancer treatment paradigm: the FACE trialExpert Review of Anticancer Therapy, 2006
- A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast CancerNew England Journal of Medicine, 2005
- Aromatase Inhibitors in the Treatment of Breast CancerEndocrine Reviews, 2005
- ATAC trial updateThe Lancet, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- The pharmacology of letrozoleThe Journal of Steroid Biochemistry and Molecular Biology, 2003
- Nonsteroidal aromatase inhibitors: Recent advancesMedicinal Research Reviews, 2002
- Aromatase inhibitors in breast cancerTrends in Endocrinology & Metabolism, 2002
- Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancersExpert Opinion on Therapeutic Patents, 2001